MX2022014440A - Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. - Google Patents
Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.Info
- Publication number
- MX2022014440A MX2022014440A MX2022014440A MX2022014440A MX2022014440A MX 2022014440 A MX2022014440 A MX 2022014440A MX 2022014440 A MX2022014440 A MX 2022014440A MX 2022014440 A MX2022014440 A MX 2022014440A MX 2022014440 A MX2022014440 A MX 2022014440A
- Authority
- MX
- Mexico
- Prior art keywords
- administering
- inhibitor
- methods
- eosinophilic esophagitis
- treating eosinophilic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029085P | 2020-05-22 | 2020-05-22 | |
| US202063066705P | 2020-08-17 | 2020-08-17 | |
| US202063071264P | 2020-08-27 | 2020-08-27 | |
| US202063088147P | 2020-10-06 | 2020-10-06 | |
| US202063121088P | 2020-12-03 | 2020-12-03 | |
| US202163144939P | 2021-02-02 | 2021-02-02 | |
| EP21315068 | 2021-04-21 | ||
| PCT/US2021/033693 WO2021237110A1 (en) | 2020-05-22 | 2021-05-21 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014440A true MX2022014440A (es) | 2023-02-27 |
Family
ID=76444669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014440A MX2022014440A (es) | 2020-05-22 | 2021-05-21 | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250154267A2 (enExample) |
| EP (1) | EP4153300A1 (enExample) |
| JP (1) | JP2023527775A (enExample) |
| KR (1) | KR20230015965A (enExample) |
| CN (1) | CN115768516A (enExample) |
| AU (1) | AU2021277398A1 (enExample) |
| BR (1) | BR112022022235A2 (enExample) |
| CA (1) | CA3174431A1 (enExample) |
| IL (1) | IL298257A (enExample) |
| MX (1) | MX2022014440A (enExample) |
| WO (1) | WO2021237110A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| HRP20181227T1 (hr) | 2012-09-07 | 2018-10-05 | Regeneron Pharmaceuticals, Inc. | Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| RU2704999C2 (ru) | 2014-02-28 | 2019-11-01 | Ридженерон Фармасьютикалз, Инк. | Способ лечения кожной инфекции путем введения антагониста il-4r |
| EA037960B1 (ru) | 2016-04-27 | 2021-06-15 | Эббви Инк. | Способ лечения эозинофильного эзофагита с применением антитела против il-13 |
| CN109789196B (zh) | 2016-09-01 | 2024-03-19 | 瑞泽恩制药公司 | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 |
| EP3793597A1 (en) | 2018-05-13 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
| MA55372A (fr) | 2019-03-21 | 2022-01-26 | Regeneron Pharma | Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie |
| AU2020326713A1 (en) | 2019-08-05 | 2022-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| CN114173819A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 |
| US20230340601A1 (en) * | 2022-04-26 | 2023-10-26 | Regeneron Pharmaceuticals, Inc. | Transcriptome Analysis For Treating Inflammation |
| MA71395A (fr) * | 2022-07-08 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement de l'oesophagite à éosinophiles chez un sujet pédiatrique par administration d'un antagoniste d'il-4 r |
| TW202502820A (zh) | 2023-03-27 | 2025-01-16 | 美商再生元醫藥公司 | 藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法 |
| WO2025221247A1 (en) * | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE16192152T1 (de) | 2000-05-26 | 2020-08-06 | Immunex Corporation | Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| GEP20104991B (en) | 2003-11-07 | 2010-05-25 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
| WO2006083390A2 (en) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2008054606A2 (en) | 2006-10-02 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| PL2624865T3 (pl) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R) |
| JP6013915B2 (ja) * | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TWI634900B (zh) * | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| EA037960B1 (ru) * | 2016-04-27 | 2021-06-15 | Эббви Инк. | Способ лечения эозинофильного эзофагита с применением антитела против il-13 |
| CN107474134B (zh) | 2016-06-08 | 2021-07-27 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| TWI777515B (zh) * | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| IL315556A (en) * | 2017-08-04 | 2024-11-01 | Regeneron Pharma | Methods for treating active eosinophilic esophagitis |
| WO2019165138A1 (en) * | 2018-02-21 | 2019-08-29 | Adare Development I, L.P. | Methods of managing eosinophilic esophagitis |
| KR102880460B1 (ko) * | 2018-06-14 | 2025-11-06 | 아지노모토 가부시키가이샤 | 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염 |
| EP3878868B1 (en) | 2018-11-09 | 2024-10-09 | Ajou University Industry-Academic Cooperation Foundation | Human antibody having high affinity to human il-4 receptor alpha, and use thereof |
-
2021
- 2021-05-21 KR KR1020227045054A patent/KR20230015965A/ko active Pending
- 2021-05-21 AU AU2021277398A patent/AU2021277398A1/en active Pending
- 2021-05-21 US US17/327,504 patent/US20250154267A2/en active Pending
- 2021-05-21 WO PCT/US2021/033693 patent/WO2021237110A1/en not_active Ceased
- 2021-05-21 CN CN202180036330.4A patent/CN115768516A/zh active Pending
- 2021-05-21 EP EP21732754.3A patent/EP4153300A1/en active Pending
- 2021-05-21 JP JP2022571133A patent/JP2023527775A/ja active Pending
- 2021-05-21 CA CA3174431A patent/CA3174431A1/en active Pending
- 2021-05-21 IL IL298257A patent/IL298257A/en unknown
- 2021-05-21 BR BR112022022235A patent/BR112022022235A2/pt unknown
- 2021-05-21 MX MX2022014440A patent/MX2022014440A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL298257A (en) | 2023-01-01 |
| JP2023527775A (ja) | 2023-06-30 |
| AU2021277398A1 (en) | 2023-02-02 |
| CN115768516A (zh) | 2023-03-07 |
| EP4153300A1 (en) | 2023-03-29 |
| BR112022022235A2 (pt) | 2023-03-28 |
| US20250154267A2 (en) | 2025-05-15 |
| KR20230015965A (ko) | 2023-01-31 |
| CA3174431A1 (en) | 2021-11-25 |
| US20210363264A1 (en) | 2021-11-25 |
| WO2021237110A1 (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014440A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| CL2025002241A1 (es) | Anticuerpos de b7-h4 y métodos para usarlos | |
| CY1124095T1 (el) | Μεθοδοι για την ενισχυση της ειδικης ανοσοθεραπειας εναντι αλλεργιογονου με χορηγηση αναστολεα του ιl-4r | |
| CO2022013525A2 (es) | Anticuerpos contra sars-cov-2 y métodos para usarlos | |
| CY1122909T1 (el) | Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r | |
| CL2022000127A1 (es) | Anticuerpos que se fijan a gprc5d | |
| MX387530B (es) | Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migraña. | |
| CO2021007053A2 (es) | Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn | |
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| AU2014284235B2 (en) | Methods for treating nasal polyposis by administering an IL-4R antagonist | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| BR112014008764A8 (pt) | Usos de um anticorpo, anticorpo, composição farmacêutica e combinação para o tratamento de artrite reumatoide | |
| MX2025007846A (es) | Metodo de uso de un coagonista de gip/glp1 para la diabetes | |
| MX2018013172A (es) | Metodos para el tratamiento de las enfermedades en las que es perjudicial la actividad de la il-13, a traves del uso de los anticuerpos anti-il-13. | |
| MX2022011730A (es) | Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r. | |
| EA201590720A8 (ru) | АНТИ-Flt-1-АНТИТЕЛА В ЛЕЧЕНИИ МЫШЕЧНОЙ ДИСТРОФИИ ДЮШЕНА | |
| PH12022550246A1 (en) | A dosing regimen for an ido inhibitor | |
| MX2025011152A (es) | Metodos para el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc) mediante la administracion de un antagonista de il-4r | |
| CO2024001388A2 (es) | Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2 | |
| MX2025005113A (es) | Metodos para tratar la dermatitis de manos y pies mediante la administracion de un antagonista de il-4r | |
| MX2024002072A (es) | Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r. | |
| MX2025011114A (es) | Metodos para el tratamiento de la gastroenteritis eosinofilica mediante la administracion de un antagonista de il-4r | |
| MX2024015797A (es) | Metodos para el tratamiento de esofagitis eosinofilica en pacientes pediatricos mediante la administracion de un antagonista de il-4r | |
| MX2022004164A (es) | Anticuerpos anti-flt-1 para tratar displasia broncopulmonar. | |
| MX2022006812A (es) | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. |